skip navigation links
National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 14.12e (Release date: 2014-12-29-08:00)
SearchBox Top
SearchBox Bottom
Pacritinib (Code C78837)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: Pacritinib

Definition: An orally bioavailable inhibitor of Janus kinase 2 (JAK2) and the JAK2 mutant JAK2V617F with potential antineoplastic activity. Oral JAK2 inhibitor SB1518 competes with JAK2 for ATP binding, which may result in inhibition of JAK2 activation, inhibition of the JAK-STAT signaling pathway, and so caspase-dependent apoptosis. JAK2 is the most common mutated gene in bcr-abl-negative myeloproliferative disorders; the JAK2V617F gain-of-function mutation involves a valine-to-phenylalanine modification at position 617. The JAK-STAT signaling pathway is a major mediator of cytokine activity.

Display Name: Pacritinib

Label: Pacritinib

NCI Thesaurus Code: C78837 (Search for linked caDSR metadata)

Synonyms & Abbreviations: (see Synonym Details)
Oral JAK2 Inhibitor SB1518
Pacritinib
PACRITINIB
SB1518

External Source Codes: 
CAS Registry Number 937272-79-2 (see NLM ChemIDplus info)
FDA UNII Code G22N65IL3O
PDQ Closed Trial Search ID 609888 (check for NCI PDQ closed clinical trial info)
PDQ Open Trial Search ID 609888 (check for NCI PDQ open clinical trial info)
UMLS CUI C2703133

Other Properties:
Chemical_Formula C28H32N4O3
code C78837
Contributing_Source CTRP
Contributing_Source FDA
Legacy_Concept_Name JAK2_Inhibitor_SB1518
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  

URL: http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C78837&ns=NCI_Thesaurus

Mainbox Bottom